Riociguat (BAY 63-2521) is a potent and selective sGC stimulator and is a first-in-class sGC stimulator approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) [21]. The gene discussed is SGCB; the disease is pulmonary arterial hypertension.